Procter & Gamble Health Limited Books ₹32 Crore Profit from Mumbai Property Sale

Procter & Gamble Health Limited (PGHL) has announced the successful sale of immovable properties in Mumbai, generating a substantial profit of ₹32 crores for the healthcare company. The transaction was finalized on April 30, 2026, marking a significant asset disposal for the organization.

The company executed an indenture of sale for the disposal of certain immovable properties situated in Mumbai. This strategic move is expected to contribute positively to the company's financial performance. The transaction details include the following:

- Transaction Date: April 30, 2026 - Property Location: Mumbai - Expected Profit: Approximately ₹32 crores - Transaction Type: Sale of immovable properties

Procter & Gamble Health Limited has fulfilled its regulatory obligations by informing both major stock exchanges about this material transaction. The company submitted the required intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 to:

- BSE Limited (Scrip Code: 500126) - National Stock Exchange of India Limited (Scrip Code: PGHL)

The property sale is projected to generate approximately ₹32 crores in profit for Procter & Gamble Health Limited. This significant gain from the disposal of real estate assets demonstrates the company's ability to optimize its asset portfolio and generate value from non-core holdings.

The regulatory filing was digitally signed by Zeal Rupani, Company Secretary of Procter & Gamble Health Limited, on April 30, 2026, at 22:41:29 +05'30'. The formal communication ensures transparency and compliance with stock exchange requirements for material events that could impact investor decisions.

Procter & Gamble Health Limited is a subsidiary of Procter & Gamble, a leading multinational consumer goods corporation. The company focuses on healthcare products and has a strong presence in various markets, including India. The sale of the Mumbai property is part of the company's broader strategy to streamline its operations and focus on core business activities.

Historical stock returns for Procter & Gamble Health Limited are as follows:

- 1 Day: +1.59% - 5 Days: +1.64% - 1 Month: +7.40% - 6 Months: -15.72% - 1 Year: +2.06% - 5 Years: -18.15%

These returns reflect the company's performance in the stock market, which can be influenced by various factors, including the recent property sale.

The company's decision to sell the Mumbai property is a strategic move that aligns with its financial goals and regulatory compliance. The proceeds from the sale will likely be used to fund further business initiatives, such as research and development, acquisitions, or debt reduction, thereby strengthening the company's financial position.

In addition to the property sale, Procter & Gamble Health Limited has also confirmed its non-large corporate status under SEBI's framework for fund raising by large entities. The company reported nil outstanding borrowings as of March 31, 2026, and confirmed that credit rating requirements are not applicable. This disclosure was made in compliance with SEBI circulars regarding fund raising by large entities, with Company Secretary Zeal Rupani signing the formal notification on April 6, 2026.

Under the SEBI framework, entities classified as Large Corporates are subject to specific borrowing requirements through debt securities. The regulations include provisions for fines in case of shortfall in mandatory borrowing through debt markets. Beginning from FY2022, a fine of 0.20% of the shortfall is levied by stock exchanges at the end of the two-year block period.

The disclosure was signed digitally by Company Secretary Zeal Rupani on April 6, 2026, at 10:33:45 +05'30'. The company has requested both BSE and NSE to acknowledge receipt of this compliance disclosure, demonstrating adherence to regulatory transparency requirements.

Overall, the successful sale of the Mumbai property and the company's non-large corporate status under SEBI's framework highlight Procter & Gamble Health Limited's commitment to financial prudence and regulatory compliance.